参考文献/References:
[1] Kovacs G,Bartolome S,Denton CP,et al. Definition,classification and diagnosis of pulmonary hypertension[J]. Eur Respir J,2024,64(4):2401324.
[2] Guignabert C,Dorfmüller P. Pathology and pathobiology of pulmonary hypertension[J]. Semin Respir Crit Care Med,2017,38(5):571-584.
[3] Han S,Chandel NS. Lessons from cancer metabolism for pulmonary arterial hypertension and fibrosis[J]. Am J Respir Cell Mol Biol,2021,65(2):134-145.
[4] Cruzat V,Macedo Rogero M,Noel Keane K,et al. Glutamine:metabolism and immune function,supplementation and clinical translation[J]. Nutrients,2018,10(11):1564.
[5] Zhang J,Pavlova NN,Thompson CB. Cancer cell metabolism:the essential role of the nonessential amino acid,glutamine[J]. EMBO J,2017,36(10):1302-1315.
[6] Piao L,Fang YH,Parikh K,et al. Cardiac glutaminolysis:a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension[J]. J Mol Med (Berl),2013,91(10):1185-1197.
[7] Yanagisawa R,Kataoka M,Inami T,et al. Usefulness of circulating amino acid profile and Fischer ratio to predict severity of pulmonary hypertension[J]. Am J Cardiol,2015,115(6):831-836.
[8] Bertero T,Oldham WM,Cottrill KA,et al. Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension[J]. J Clin Invest,2016,126(9):3313-3335.
[9] Chen Y,Tan L,Gao J,et al. Targeting glutaminase 1(GLS1) by small molecules for anticancer therapeutics[J]. Eur J Med Chem,2023,252:115306.
[10] Stenmark KR,Tuder RM,El Kasmi KC. Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension[J]. J Appl Physiol (1985),2015,119(10):1164-1172.
[11] Liu H,Sun M,Wu N,et al. TGF-β/Smads signaling pathway,Hippo-YAP/TAZ signaling pathway,and VEGF:their mechanisms and roles in vascular remodeling related diseases[J]. Immun Inflamm Dis,2023,11(11):e1060.
[12] Bertero T,Cottrill KA,Lu Y,et al. Matrix remodeling promotes pulmonary hypertension through feedback mechanoactivation of the YAP/TAZ-miR-130/301 circuit[J]. Cell Rep,2015,13(5):1016-1032.
[13] Torrence ME,MacArthur MR,Hosios AM,et al. The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals[J]. Elife,2021,10:e63326.
[14] Kim M,Hwang S,Kim B,et al. YAP governs cellular adaptation to perturbation of glutamine metabolism by regulating ATF4-mediated stress response[J]. Oncogene,2023,42(38):2828-2840.
[15] Koo JH,Guan KL. Interplay between YAP/TAZ and metabolism[J]. Cell Metab,2018,28(2):196-206.
[16] Yang CS,Stampouloglou E,Kingston NM,et al. Glutamine-utilizing transaminases are a metabolic vulnerability of TAZ/YAP-activated cancer cells[J]. EMBO Rep,2018,19(6):e43577.
[17] Wang L,Chennupati R,Jin YJ,et al. YAP/TAZ are required to suppress osteogenic differentiation of vascular smooth muscle cells[J]. iScience,2020,23(12):101860.
[18] Zou Z,Tao T,Li H,et al. mTOR signaling pathway and mTOR inhibitors in cancer:progress and challenges[J]. Cell Biosci,2020,10:31.
[19] Wang W,Liu J,Ma A,et al. mTORC1 is involved in hypoxia-induced pulmonary hypertension through the activation of Notch3[J]. J Cell Physiol,2014,229(12):2117-2125.
[20] Pena A,Kobir A,Goncharov D,et al. Pharmacological inhibition of mTOR kinase reverses right ventricle remodeling and improves right ventricle structure and function in rats[J]. Am J Respir Cell Mol Biol,2017,57(5):615-625.
[21] Durán RV,Oppliger W,Robitaille AM,et al. Glutaminolysis activates Rag-mTORC1 signaling[J]. Mol Cell,2012,47(3):349-358.
[22] Kim J,Kim E. Rag GTPase in amino acid signaling[J]. Amino Acids,2016,48(4):915-928.
[23] Laggner M,Hacker P,Oberndorfer F,et al. The roles of S100A4 and the EGF/EGFR signaling axis in pulmonary hypertension with right ventricular hypertrophy[J]. Biology (Basel),2022,11(1):118.
[24] Rafikova O,Rafikov R,Kangath A,et al. Redox regulation of epidermal growth factor receptor signaling during the development of pulmonary hypertension[J]. Free Radic Biol Med,2016,95: 96-111.
[25] Yu X,Zhao X,Zhang J,et al. Dacomitinib, a new pan-EGFR inhibitor, is effective in attenuating pulmonary vascular remodeling and pulmonary hypertension[J]. Eur J Pharmacol,2019,850:97-108.
[26] Weerasekara VK,Patra KC,Bardeesy N. EGFR pathway links amino acid levels and induction of macropinocytosis[J]. Dev Cell,2019,50(3):261-263.
[27] Yang R,Li X,Wu Y,et al. EGFR activates GDH1 transcription to promote glutamine metabolism through MEK/ERK/ELK1 pathway in glioblastoma[J]. Oncogene,2020,39(14):2975-2986.
[28] Shi J,Yang Y,Cheng A,et al. Metabolism of vascular smooth muscle cells in vascular diseases[J]. Am J Physiol Heart Circ Physiol,2020,319(3):H613-H631.
[29] Osman I,He X,Liu J,et al. TEAD1(TEA domain transcription factor 1) promotes smooth muscle cell proliferation through upregulating SLC1A5(solute carrier family 1 member 5)-mediated glutamine uptake[J]. Circ Res,2019,124(9):1309-1322.
[30] Park HY,Kim MJ,Lee S,et al. Inhibitory effect of a glutamine antagonist on proliferation and migration of VSMCs via simultaneous attenuation of glycolysis and oxidative phosphorylation[J]. Int J Mol Sci,2021,22(11):5602.
[31] Leopold JA,Maron BA. Molecular mechanisms of pulmonary vascular remodeling in pulmonary arterial hypertension[J]. Int J Mol Sci,2016,17(5):761.
[32] Zhang CY,Hu YC,Zhang Y,et al. Glutamine switches vascular smooth muscle cells to synthetic phenotype through inhibiting miR-143 expression and upregulating THY1 expression[J]. Life Sci,2021,277:119365.
[33] Shi XF, Su YC. Vascular metabolic mechanisms of pulmonary hypertension[J]. Curr Med Sci,2020,40(3):444-454.
[34] Wang Z,Yemanyi F,Blomfield AK,et al. Amino acid transporter SLC38A5 regulates developmental and pathological retinal angiogenesis[J]. Elife,2022,11:e73105.
[35] Eelen G,Dubois C,Cantelmo AR,et al. Role of glutamine synthetase in angiogenesis beyond glutamine synthesis[J]. Nature,2018,561(7721): 63-69.
[36] Huang H,Vandekeere S,Kalucka J,et al. Role of glutamine and interlinked asparagine metabolism in vessel formation[J]. Embo j,2017,36(16):2334-2352.
[37] Hernandez-Saavedra D,Sanders L,Freeman S,et al. Stable isotope metabolomics of pulmonary artery smooth muscle and endothelial cells in pulmonary hypertension and with TGF-beta treatment[J]. Sci Rep,2020,10(1):413.
[38] Hu Y,Chi L,Kuebler WM,et al. Perivascular Inflammation in Pulmonary Arterial Hypertension[J]. Cells,2020,9(11):2338.
[39] Ryan JJ,Archer SL. The right ventricle in pulmonary arterial hypertension:disorders of metabolism,angiogenesis and adrenergic signaling in right ventricular failure[J]. Circ Res,2014,115(1):176-188.
[40] Wang S,Yan Y,Xu WJ,et al. The role of glutamine and glutaminase in pulmonary hypertension[J]. Front Cardiovasc Med,2022,9:838657.
相似文献/References:
[1]孟晓冬,单福祥,综述,等.肺动脉高压治疗进展[J].心血管病学进展,2016,(3):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
MENG Xiaodong,SHAN Fuxiang,WANG Yanhui.Advances in Research of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2016,(8):319.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.028]
[2]张艺韬,综述,曾伟杰,等.左心疾病相关肺动脉高压流行病学[J].心血管病学进展,2016,(4):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
ZHANG Yitao,ZENG Weijie,CHENG Kanglin.Epidemiology of Pulmonary Hypertension due to Left Heart Disease[J].Advances in Cardiovascular Diseases,2016,(8):333.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.002]
[3]汪汉,刘英杰,王燕凤.长链非编码RNA与肺动脉高压[J].心血管病学进展,2019,(6):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
WANG Han,LIU Yingjie,WANG Yanfeng.Long Non-coding RNA in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):898.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.015]
[4]汪汉 邓祁 刘英杰.系统性红斑狼疮相关肺动脉高压的诊断、治疗及预后[J].心血管病学进展,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
WANG Han,DENG Qi,LIU Yingjie.Diagnosis,Treatment and Prognosis of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2019,(8):1142.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.018]
[5]段宇 贾静 步睿 李涛 韦宏.急性伊洛前列素吸入对肺动脉高压患者右心室功能的影响[J].心血管病学进展,2019,(9):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
DUAN Yu,JIA Jing,BU Rui,et al.The Effect of Acute Iloprost Inhalation on Right Ventricular Function in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(8):1319.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.034]
[6]查玉杰 何庆.肺动脉高压发生发展中的相关因子[J].心血管病学进展,2020,(2):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
ZHA YujieHE Qing.The Relevant Factors in the Development of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):192.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.024]
[7]朱珊英,朱国斌.肺动脉高压发病机制新进展[J].心血管病学进展,2020,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
ZHU Shanying,ZHU Guobin.Pathogenesis of Pulmonary Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):292.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.019]
[8]韩柯,孟祥光,赵育洁.趋化因子及其受体在肺动脉高压中的研究进展[J].心血管病学进展,2020,(3):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
HAN Ke,MENG Xiangguang,ZHAO Yujie.Chemokines and Their Receptors in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):296.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.020]
[9]刘超 曲杰 王明娟 徐倩 范彦芳 周晓慧 单伟超.肺动脉高压对扩张型心肌病预后的影响[J].心血管病学进展,2020,(4):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
LIU ChaoQU JieWANG MingjuanXU QianFAN YanfangZHOU XiaohuiSAN Weichao.The Effect of Pulmonary Hypertension on the Prognosis of Dilated Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(8):424.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.023]
[10]向杰 刘明鑫 张伟 黄从新.基于生物信息学分析探究肺动脉高压关键基因和通路[J].心血管病学进展,2020,(4):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]
Xiang JieLiu MingxinZhang WeiHuang Congxin.Bioinformatics Analysis of Key Genes and Pathways in Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2020,(8):428.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.024]